Skip to main content

Table 1 Baseline characteristics of the ISS T-002 and ISS OBS T-002 study participants

From: HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

 

ISS T-002

ISS OBS T-002

p-value d

( n  = 155)

( n  = 79)

Age

   

Mean ± s.d.a

41 ± 7

42 ± 6

0.6323

Range

24-55

24-55

 

Gender

   

Male

83%

75%

0.1200

Female

17%

25%

 

CD4 + nadir (cells/μl)

   

Mean ± s.d.

308 ± 133

219 ± 140

<0.0001

Range

14-846

2-612

 

CD4 + (cells/μl)

   

Mean ± s.d.

639 ± 220

657 ± 271

0.5450

Range

212-1490

208-1527

 

CD4 + (%)

   

Mean ± s.d.

33 ± 8

31 ± 8

0.0257

Range

14-61

12-52

 

HIV RNA (copies/ml)

<50b

<50c

 

Years from diagnosis of HIV

   

Mean ± s.d.

9 ± 6

11 ± 7

0.1789

Range

1-25

1-24

 

Years from HAART initiation

   

Mean ± s.d.

6 ± 4

6 ± 5

0.4984

Range

0-19

0-19

 

Current HAART regimen

   

NNRTI-based or NRTI

68%

62%

0.3305

PI-based

32%

38%

 
  1. n indicates the number of evaluable individuals; aStandard deviation; bFive subjects had values >50 copies/ml (between 58 and 91); cFour subjects had values >50 copies/ml (between 64 and 118);
  2. d t-test was applied for continuous variables, Chi-square test was applied for categorical variables.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us